Natalizumab for 2nd Line Treatment in Relapsing-Remitting Multiple Sclerosis Patients: 5-Year Budget Impact Analysis (BIA) from the Brazilian Public Payer Perspective
| Autor: | A.M. Nishikawa, Otavio Clark, A.L. Liamas, C.C. Bueno, Luciano Paladini |
|---|---|
| Rok vydání: | 2013 |
| Předmět: |
medicine.medical_specialty
business.industry Multiple sclerosis Health Policy Perspective (graphical) Public Health Environmental and Occupational Health Budget impact medicine.disease Natalizumab Relapsing remitting medicine Physical therapy Line (text file) Intensive care medicine business medicine.drug |
| Zdroj: | Value in Health. 16(7) |
| ISSN: | 1098-3015 |
| DOI: | 10.1016/j.jval.2013.08.2240 |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect